Meeting
2019 Genitourinary Cancers Symposium
SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.
Authors
Gretchen Hoyer
University of Colorado Anschutz Medical Campus, Aurora, CO
Gretchen Hoyer , E. David Crawford , Paul Arangua , Whitney Stanton , Francisco G. La Rosa , Wendy Poage , M. Scott Lucia , Adrie van Bokhoven , Priya N. Werahera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 30)
DOI
10.1200/JCO.2019.37.7_suppl.30
Abstract #
30
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.
First Author: Michael J. Donovan
Poster
2015 Genitourinary Cancers Symposium
A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate needle biopsy.
First Author: Michael J. Donovan
Poster
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
First Author: Ekamjit Singh Deol
Poster
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
First Author: Paras Shah